GlassScriptPhysician profile
Gabriel E Gemayel
NPI 1790769735
$8,310.22
in general payments reported to CMS, 2019-2025
36 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,173 · 2020: $355 · 2021: $1,011 · 2022: $1,018 · 2023: $1,384 · 2024: $1,354 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,753.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,170.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,002.16 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $960.58 | 2019-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $613.66 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $571.26 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $560.45 | 2021-2025 | |
| Pfizer INC. | $512.29 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $422.53 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $412.55 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $400.29 | 2019-2024 | Tradjenta, Jardiance |
| Amgen INC. | $392.98 | 2022-2025 | Repatha, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $128.34 | 2019-2022 | |
| Exact Sciences Corporation | $126.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $112.60 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Merck Sharp & Dohme LLC | $98.42 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $82.24 | 2021-2024 | Austedo Xr |
| Boston Scientific Corporation | $66.23 | 2024-2025 | Wavewriter Alpha Prime 16, Watchman Flx |
| Kowa Pharmaceuticals America, INC. | $64.77 | 2022-2025 | Zoryve |
| Gilead Sciences, INC. | $61.72 | 2022-2024 | |
| Arbor Pharmaceuticals, INC. | $57.40 | 2019-2020 | |
| Dexcom, INC. | $57.03 | 2024-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $51.40 | 2019-2021 | |
| Shield Therapeutics INC | $50.74 | 2023 | Accrufer |
| Janssen Pharmaceuticals, INC | $49.92 | 2019 | |
| Allergan, INC. | $38.30 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $35.94 | 2025 | Keveyis, Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $33.50 | 2022-2023 | Quviviq |
| Sumitomo Pharma America, INC. | $26.03 | 2023 | Gemtesa |
| Neurocrine Biosciences, INC. | $21.34 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.81 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $20.76 | 2022 | |
| Sunovion Pharmaceuticals INC. | $20.68 | 2021 | |
| Medtronic, INC. | $20.15 | 2022 | |
| Vanda Pharmaceuticals INC. | $16.70 | 2020 | |
| Circassia INC. | $16.22 | 2019 | |
| Eisai INC. | $13.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Gemayel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.